Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects (Q46171594)

20 December 2017

title

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects (English)

1 reference

20 December 2017

author name string

B Komoroski

1

1 reference

20 December 2017

N Vachharajani

2

1 reference

20 December 2017

D Boulton

3

1 reference

20 December 2017

D Kornhauser

4

1 reference

20 December 2017

M Geraldes

5

1 reference

20 December 2017

L Li

6

1 reference

20 December 2017

M Pfister

7

1 reference

20 December 2017

language of work or name

English

0 references

publication date

7 January 2009

1 reference

20 December 2017

number of pages

7

1 reference

Clinical Pharmacology & Therapeutics

inferred from page(s)

published in

1 reference

20 December 2017

volume

85

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

page(s)

520-526

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/clpt.2008.251

exact match

0 references

cites work

Management of type 2 diabetes: a challenge for patient and physician

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Current therapies and emerging targets for the treatment of diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Hyperglycemia and microvascular and macrovascular disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Diabetes complications: why is glucose potentially toxic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Type 2 diabetes mellitus: what is the optimal treatment regimen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

First approved inhaled insulin therapy for diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Active sugar transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Glucose transporters: structure, function and consequences of deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Familial renal glucosuria: SLC5A2 mutation analysis and evidence of salt-wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Physiological and behavioral aspects of glycemic control and hypoglycemia in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

7 January 2021

inferred from DOI database lookup

T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

7 January 2021

inferred from DOI database lookup

T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2008.251

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/CLPT.2008.251

1 reference

20 December 2017

Dimensions Publication ID

0 references

1 reference

20 December 2017